Quoted from http://www.inpharm.com/news/171671/boehringer-s-pradaxa-website-censured
Boehringer’s Pradaxa website censuredPublished on 08/03/12 at 11:46am
Boehringer's Pradaxa website
Boehringer Ingelheim has breached the ABPI’s Code of Conduct over the use of its Pradaxa website.
Pradaxa is a new oral blood thinner with several licences to prevent blood clots and reduce the risk of stroke in certain patients.
Boehringer’s website was suppose to be for medical professionals only, but an anonymous GP said that access to the site’s medical content was “not sufficiently rigorous to restrict access to health professionals only”.
The GP alleges that because of this, Boehringer Ingelheim “clearly intended to facilitate the promotion of Pradaxa to the public”.
The PMPCA, who monitors adherence to the Code, did not agree that the site was being used to advertise to the public.
It did however, find that Boehringer had breached Clause 4.6 of the Code, because the site was found to be promoting Pradaxa but did not give a clear, prominent statement as to where the prescribing information can be found.
The anonymous GP said that the location of the prescribing information was only clarified after prominent claims for Pradaxa - and the PMCPA agreed.
[Article continues at original source]